AMOXIL ORAL SUSP Rx
Generic Name and Formulations:
Amoxicillin (as trihydrate) 250mg/5mL, 400mg/5mL; bubble-gum flavor.
Dr. Reddy's Laboratories, Inc.
Indications for AMOXIL ORAL SUSP:
Susceptible infections including ear/nose/throat (ENT), lower respiratory tract, skin and skin structure, genitourinary tract, acute uncomplicated gonorrhea.
Mild to moderate ENT, skin, or genitourinary: 500mg every 12hrs or 250mg every 8hrs. Lower respiratory or severe ENT, skin, or genitourinary: 875mg every 12hrs or 500mg every 8hrs. Gonorrhea: 3g once. Severe renal impairment (CrCl <30mL/min): 875mg tabs not recommended; CrCl 10–30mL/min: 250–500mg every 12hrs; CrCl <10mL/min: 250–500mg every 24hrs (give additional doses during and after hemodialysis).
For treating acute otitis media: The AAP recommends 80–90mg/kg per day in divided doses (note: this is not an FDA-approved dose). Do not exceed recommended adult dose. >40kg: dose as adults. Neonates and infants ≤3months: max 30mg/kg per day in divided doses every 12hrs. >3months: Mild to moderate ENT, skin, or genitourinary: 25mg/kg per day in divided doses every 12hrs or, 20mg/kg per day in divided doses every 8hrs. Lower respiratory or severe ENT, skin, or genitourinary: 45mg/kg per day in divided doses every 12hrs or, 40mg/kg per day in divided doses every 8hrs. Gonorrhea: ≤2yrs: not recommended; >2yrs: 50mg/kg with 25mg/kg probenecid once. Renal dysfunction: not recommended.
Cephalosporin, imipenem, other allergy or mononucleosis: not recommended. Monitor blood, renal, and hepatic function in long-term use. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln.
GI upset, hypersensitivity reactions (eg, urticaria, rash, Stevens-Johnson syndrome, anaphylaxis), hyperactivity, blood dyscrasias.
Caps—500; Susp 250mg/5mL—100mL, 150mL; Susp 400mg/5mL—100mL; Drops 50mg/mL—30mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma